Pliant Therapeutics discontinues bexotegrast in IPF; Q2 net loss narrows to $43.3M

PLIANT THERAPEUTICS, INC.

2025-Q2 EPS reported -$1.62 vs consensus -$0.71 ▼ miss (-128.4%)

Bexotegrast development in IPF stopped due to unfavorable risk-benefit; full BEACON-IPF data to be published.
Phase 1 trial of PLN-101095 in solid tumors ongoing; data from top two dose cohorts expected by end of 2025.
Workforce restructuring largely complete; cash, cash equivalents and short-term investments at $264.4M as of June 30.
Q2 R&D expenses fell to $32.2M from $45.6M; G&A dropped to $13.4M from $15.0M.
Net loss of $43.3M improved from $55.9M in prior-year quarter, driven by restructuring and trial discontinuation.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.